Immunodiagnosis of Systemic Lupus Erythematosus (SLE) in a tertiary care hospital

  • Latha Ragunathan Aarupadai veedu medical college & hospital, Pondicherry India
  • Anandi Chidambaram Vinayaka Missions Medical College & Hospitals – Karaikal India
  • Kavitha Kannaiyan Aarupadai veedu medical college & hospital, Pondicherry India
  • Chidambaram N Rajah Muthiah Medical college, Chidambaram India
Keywords: Autoantibodies, systemic lupus erythematosus, SLE, ANA, Ds-DNA, Lupus


Objectives To diagnose patients with Systemic lupus erythematosus clinically and compare various immunological tests available to detect their specificity and sensitivity of the various parameters employed. Methods It was a hospital-based cross-sectional study. All patients satisfying the revised American College of Rheumatology criteria (1982) for SLE were included in the study over a period of 3 years. A total of two hundred and four individuals were included. The patients were divided into three groups- (Group I- Confirmed SLE patients-32, Group II- Incomplete SLE patients- 60, and Group III -patients with other autoimmune disorders- 42) and 70 persons were included as controls. Results Patients were divided into three groups I, II, III and their clinical & laboratory features were compared. Females (90.6%) were more affected than males (9.4%) and 69% were in the age group of 20-40 years. The average age of onset of disease was 24.4 years. Predominant clinical features were arthritis (81.25%), skin rashes (72%), myalgia (68.75%), alopecia (68.75%), fever (65%) and oral ulcers 18(56.25%). Anti-ds-DNA test and ANA test were positive in all the patients and the anti-DNP test was positive in 59.3% patients. Females were more affected (81.7%) than males (18.3%). 85% were between 21-50 years The average age of patients was 30.16 years with a range of 10-70 years. Patients were regularly followed up and 32 patients (26.67%) developed complete SLE. The most common manifestations were arthritis (88.3%), fever (43.3%) skin rashes (68.3%). 10.34% of ILE patients developed full SLE and all were females. Average age of disease onset was 24years. Anti-ds-DNA antibodies was detected in 28 patients (23.4%), ANA in (25%) patients and Anti-DNP antibodies in 12 (10%) patients. Females (81%) were affected than males (19%). 86% were between 21-50 years. The average age of patients was 33.24 years. The predominant clinical features were arthritis (78.6%) and myalgia (76.2%). Anti-ds-DNA antibodies were detected in 6%, ANA in 35.7% patients & Anti-DNP antibodies in 3.6%. Antibodies to ds-DNA were present in low titers in this group. Conclusion  A clear separation between SLE and other autoimmune disorder was found with the anti-ds-DNA test. It has a high specificity for the differential diagnosis of SLE. Our study, comparing three assays with respect to their ability to predict disease activity, indicated that ds- DNA ELISA is the best method.

Author Biographies

Latha Ragunathan, Aarupadai veedu medical college & hospital, Pondicherry India
Dept Of Microbiology
Anandi Chidambaram, Vinayaka Missions Medical College & Hospitals – Karaikal India
Dept Of Microbiology
Kavitha Kannaiyan, Aarupadai veedu medical college & hospital, Pondicherry India
Dept Of Microbiology
Chidambaram N, Rajah Muthiah Medical college, Chidambaram India
Dept of Medicine


1. Dobkin PL, Costa DD, Fortin PR, et al. Living with lupus: A prospective Pan-Canadian study. J Rheumatol 2001; 28:2442-2448
2. Hargreaves MM, Richmond H, Morton R : Presentation of two bone marrow elements: the 'tart' cell and the 'LE' cell.Proc Mayo Clin 23:25-30, 1948.
3. Miescher P, Fauconnet M, Berand T : Experimental immunonucleophagocytes and the LE phenomenon. Exp Med Surg 11:173-177, 1953.
4. Cepellini R, Polli C, Celada F : A DNA-reacting factor in serum of a patient with Lupus erythematosus diffusers. Proc. Soc Exp Biol Med 1957;96:572-576.
5. Robbins WC, Holman HR, Deicher H, Kunkel HG: Complement fixation with cell nuclei and DNA in Lupus erythematosus. Proc Soc Exp Biol Med 96:575-579, 1957.
6. Kumar A. Indian guidelines on the management of SLE. J Indian Rheumatol Assoc 2002:10:80-96.
7. Rahman MA, Isenberg DA. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1994; 6:468-73.
8. Pisetsky DS. Anti-DNA antibodies in systemic lupus erythematosus. Rheum Dis Clin North AM 1992;18:437- 54
9. Smeenk RJ, Van den Brink HG, et al. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int 1991;11:101-7.
10. Ter Borg EJ, Horst G, Hummel EJ, et al: Measurement of increases in anti double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis and Rheum 1990;33:634-43.
11. American College of Rheumatologya (ACR 1999) Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults. Arthritis Rheum 1999;42(9):1785-96.
12. Vila LM, Alarcon GS, McGwin G Jr et al. For the LUMINA study group. Early clinical manifestations, diseases activity and damage of Systemic Lupus Erythematosus among 2 distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004; 43:358-363.
13. Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmune Rev. Dec 2002;1(6):321-8.
14. Baig MM, Shere SJ. Prevalence of autoantibodies in Saudi population. J Med 1989; 20(3,4):286-90.
15. De Vlam K, De Keyser F, Verbruggen G, et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993; 11(4):393-7.
16. Vazquez-Del Mercado M, Gonzalez-Bernaldez M, Garcia-De La Torre I. Prevalence of antinuclear antibodies in a Huichol population of Mexico. Lupus 1995; 4(2):164-5.
17. Teubner A, Tillmann HL, Schuppan D, et al. Prevalence of circulating autoantibodies in healthy individuals. Med Klin (Munich). 2002 Nov 15;97 (11):645-9.
18. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum. 1978;21:480-484.
19. Paul BJ, Muhammed Fassaludeen, Nandakumar, MV Razia. Clinical profile of Systemic lupus erythematosus in Northern Kerala. J Indian Rheumatol Assoc 2003:11:94-97.
20. Malaviya AN, Singh RR, Kumar A, De A et al. systemic lupus erythematosus in northern India: A review of 329 cases. J Assoc Physicians India 1988;36:476-480.
21. Vaidya S, Samant RS, Nadkar MY, Borges NE. Systemic lupus erythematosus- a review of 220 patients. J Indian Rheumatol Assoc 1997; 5: 14-18.
22. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum. 1978;21:480-484.
23. White R H, and D L R obbins. Clinical significance and interpretation of antinuclear antibodies. West J Med. 1987. 147:210-213.
24. Jaskowski TD, Schroder C, Martins TB et al. Screening for antinuclear antibodies by enzyme immunoassays. Am J Clin Pathol. 1996 Apr;105(4):468-7.
25. Arbuckle MR, James JA, Kohlhase KF, et al. Development of anti- dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol.Jul-Aug 2001;54(1-2):211-9.
26. Greer JM and Panush RS. Incomplete lupus erythematosus. Journal Watch (General) 1989:2-2
27. Swaak AJ, van de Brink H, Smeenk RJ, et al. Incomplete lupus erythematosus: results of a multicentric study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (oxford). 2001 Jan;40(1):89-94.
28. Vila LM, Mayor AM, Valentin AH, et al. Clinical outcome and predictors of disease evolution in incomplete lupus erythematosus. Lupus. 2000;9(2):110-5.
29. Notman DD, Kurata N,Tan EM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med. 1975 Oct;83(4):464-9.
Original Article